Hybrigenics outlines financial strategy for inecalcitol
31 March 2009
Simon Varcoe
Please Login to read the full article.
31 March 2009
Simon Varcoe
simon.varcoe@informa.com
Hybrigenics is dependent on the exercise of warrants that were issued in parallel to its IPO in 2007 to progress its lead product inecalcitol to Phase IIb development, the company's CEO Dr Rémi Delansorne told Scrip.
...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
- Two-shots-on-goal deal gives Array best odds for $685M milestones in Genentech pact
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
- Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
